Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In
暂无分享,去创建一个
[1] E. Vicaut,et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. , 2013, The New England journal of medicine.
[2] Jane A. Linderbaum,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.
[3] Deepak L. Bhatt,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[4] Fred S Apple,et al. Third universal definition of myocardial infarction , 2012 .
[5] D. Atar,et al. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .
[6] A. Jaffe,et al. Why all the struggle about CK-MB and PCI? , 2012, European heart journal.
[7] Marc P. Bonaca,et al. ACC/AHA/ESC/WHF Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death: Observations from the TRITON-TIMI 38 Trial , 2011 .
[8] J. Tanguay,et al. From primary to secondary percutaneous coronary intervention: the emerging concept of early mechanical reperfusion with delayed facilitated stenting-when earlier may not be better. , 2011, The Canadian journal of cardiology.
[9] D. Yellon,et al. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. , 2011, European heart journal.
[10] G. Stone,et al. Periprocedural Myocardial Infarction: Prevalence, Prognosis, and Prevention , 2010, Circulation. Cardiovascular interventions.
[11] C. Cannon,et al. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis , 2010, Circulation.
[12] W. Ahmad. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. , 2009 .
[13] E. Antman,et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial , 2009, The Lancet.
[14] N. Danchin,et al. Pre-hospital thrombolysis in perspective. , 2008, European heart journal.
[15] E. Antman,et al. Biomarker release after percutaneous coronary intervention: a message from the heart. , 2008, Circulation. Cardiovascular interventions.
[16] M. Sabatine,et al. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. , 2008, American heart journal.
[17] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[18] D. Yellon,et al. Myocardial reperfusion injury. , 2007, The New England journal of medicine.
[19] K. Eagle,et al. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.
[20] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[21] E. Antman,et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.
[22] S. Yusuf,et al. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. , 2005, American heart journal.
[23] G. Filippatos,et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. , 2005, European heart journal.
[24] B. Lewis,et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. , 2005, JAMA.
[25] G. Lamas,et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.
[26] M. Burritt,et al. Timing of peak troponin T and creatine kinase-MB elevations after percutaneous coronary intervention. , 2004, Chest.